Integral Molecular, a research-driven biotechnology company creating therapeutic antibodies against under-exploited membrane proteins, announced lead monoclonal antibodies (MAbs) against P2X7, a target for autoimmune disorders such as atopic dermatitis and glomerulonephritis. The panel of P2X7 antibodies is fully humanized and optimized, and ready for preclinical studies.
P2X7 plays an important role in many fundamental cellular processes and is also implicated in the development and progression of different diseases, including neurodegenerative diseases, epilepsy, psychiatric disorders and cancer. Nevertheless, no drugs targeting P2X7 exist on the market until now.
The main reasons for this are the complex structure of P2X7 as well as the existence of many polymorphic forms. Apparently, Integral Molecular has found a way to overcome these obstacles.
Image by martin Andreu from Pixabay